Skip to main content

Table 4 Crude and adjusted odds ratios (OR) with 95 % confidence intervals (CI) for the association between characteristics of partnership practices and initiating long-term treatment with PPIs

From: General practice variation when initiating long-term prescribing of proton pump inhibitors: a nationwide cohort study

 

Crude OR (95 % CI)

P-value

Adjusted OR* (95 % CI)

P-value

Patients per GP

 <1350

1

.

1

.

 1350-1575

1.00 (0.93;1.07)

0.94

0.99 (0.93;1.06)

0.83

 1576-1750

0.95 (0.88;1.03)

0.19

0.98 (0.91;1.06)

0.69

 >1750

0.95 (0.88;1.04)

0.27

0.98 (0.90;1.06)

0.61

Practice location

 Capital area

1

.

1

.

 Provincial city

1.01 (0.94;1.09)

0.75

0.98 (0.90;1.05)

0.53

 Rural area

1.15 (1.06;1.24)

<0.001

1.01 (0.94;1.10)

0.74

GP gender

 Male

1

.

1

.

 Predominantly male

0.82 (0.75;0.89)

<0.001

0.85 (0.76;0.95)

<0.001

 Equally mixed

0.78 (0.71;0.85)

<0.001

0.80 (0.73;0.87)

<0.001

 Predominantly female

0.77 (0.70;0.85)

<0.001

0.83 (0.74;0.94)

<0.001

 Female

0.70 (0.62;0.79)

<0.001

0.78 (0.69;0.88)

<0.001

GP age group

 Under 45 years

1

.

1

.

 45-49 years

1.03 (0.92;1.15)

0.58

1.02 (0.91;1.14)

0.75

 50-54 years

1.08 (0.97;1.21)

0.14

1.04 (0.93;1.15)

0.50

 55-59 years

1.21 (1.08;1.35)

<0.001

1.13 (1.01;1.26)

0.03

 60-64 years

1.42 (1.23;1.63)

<0.001

1.34 (1.16;1.54)

<0.001

 65 years or above

1.54 (1.26;1.87)

<0.001

1.35 (1.11;1.64)

<0.001

Number of GPs

 2

1

.

1

.

 3

0.96 (0.90;1.03)

0.26

0.95 (0.86;1.06)

0.37

 4

0.96 (0.89;1.04)

0.36

0.99 (0.91;1.09)

0.91

 5

0.98 (0.88;1.09)

0.71

0.96 (0.83;1.10)

0.52

 >5

0.96 (0.85;1.10)

0.58

0.95 (0.82;1.10)

0.48

Training practice

 No

1

.

1

.

 Yes

1.07 (1.01;1.13)

0.03

1.08 (1.02;1.14)

<0.001

  1. *Estimates adjusted for practice characteristics and patient characteristics in terms of age, gender, specific gastrointestinal morbidity, socioeconomic status (income, educational level, cohabitation status), comedication with non-steroidal anti-inflammatory drugs (NSAIDs), antiplatelet drugs, anticoagulants, selective serotonine reuptake inhibitors (SSRIs) and comorbidity